These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 30972456)

  • 1. Rabeprazole intake does not affect systemic exposure to capecitabine and its metabolites, 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, and 5-fluorouracil.
    Sekido M; Fujita KI; Kubota Y; Ishida H; Takahashi T; Ohkuma R; Tsunoda T; Ishikawa F; Shibanuma M; Sasaki Y
    Cancer Chemother Pharmacol; 2019 Jun; 83(6):1127-1135. PubMed ID: 30972456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients.
    Di Desidero T; Orlandi P; Fioravanti A; Cremolini C; Loupakis F; Marmorino F; Antoniotti C; Masi G; Lonardi S; Bergamo F; Zagonel V; Falcone A; Bocci G
    Invest New Drugs; 2018 Aug; 36(4):709-714. PubMed ID: 29488048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Proton Pump Inhibitors on FOLFOX and CapeOx Regimens in Colorectal Cancer.
    Wong GG; Ha V; Chu MP; Dersch-Mills D; Ghosh S; Chambers CR; Sawyer MB
    Clin Colorectal Cancer; 2019 Mar; 18(1):72-79. PubMed ID: 30551953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variants of carboxylesterase 1 have no impact on capecitabine pharmacokinetics and toxicity in capecitabine plus oxaliplatin treated-colorectal cancer patients.
    Matsumoto N; Kubota Y; Ishida H; Sekido M; Ohkuma R; Ishiguro T; Hirasawa Y; Ariizumi H; Tsunoda T; Ikusue T; Kobayashi K; Hisamatsu A; Toshima H; Shimada K; Fujita KI
    Cancer Chemother Pharmacol; 2020 Jun; 85(6):1119-1128. PubMed ID: 32458030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circadian variations in the pharmacokinetics of capecitabine and its metabolites in rats.
    Kobuchi S; Yazaki Y; Ito Y; Sakaeda T
    Eur J Pharm Sci; 2018 Jan; 112():152-158. PubMed ID: 29175408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and exposure-effect relationships of capecitabine in elderly patients with breast or colorectal cancer.
    Daher Abdi Z; Lavau-Denes S; Prémaud A; Urien S; Sauvage FL; Martin J; Leobon S; Marquet P; Tubiana-Mathieu N; Rousseau A
    Cancer Chemother Pharmacol; 2014 Jun; 73(6):1285-93. PubMed ID: 24801171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous determination of capecitabine and its three nucleoside metabolites in human plasma by high performance liquid chromatography-tandem mass spectrometry.
    Deng P; Ji C; Dai X; Zhong D; Ding L; Chen X
    J Chromatogr B Analyt Technol Biomed Life Sci; 2015 May; 989():71-9. PubMed ID: 25808944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of Capecitabine and Four Metabolites in a Heterogeneous Population of Cancer Patients: A Comprehensive Analysis.
    Jacobs BAW; Deenen MJ; Joerger M; Rosing H; de Vries N; Meulendijks D; Cats A; Beijnen JH; Schellens JHM; Huitema ADR
    CPT Pharmacometrics Syst Pharmacol; 2019 Dec; 8(12):940-950. PubMed ID: 31652031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacokinetics of capecitabine.
    Reigner B; Blesch K; Weidekamm E
    Clin Pharmacokinet; 2001; 40(2):85-104. PubMed ID: 11286326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liquid chromatography-mass spectrometry method for the analysis of the anti-cancer agent capecitabine and its nucleoside metabolites in human plasma.
    Xu Y; Grem JL
    J Chromatogr B Analyt Technol Biomed Life Sci; 2003 Jan; 783(1):273-85. PubMed ID: 12450548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of co-administered drugs on drug monitoring of capecitabine in patients with advanced colorectal cancer.
    Schreiber V; Kitzmueller M; Poxhofer M; Gintersdorfer S; Neudorfer C; Lichtneckert M; Dittrich C; Czejka M
    Anticancer Res; 2014 Jul; 34(7):3371-6. PubMed ID: 24982342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients.
    Reigner B; Verweij J; Dirix L; Cassidy J; Twelves C; Allman D; Weidekamm E; Roos B; Banken L; Utoh M; Osterwalder B
    Clin Cancer Res; 1998 Apr; 4(4):941-8. PubMed ID: 9563888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic and pharmacodynamic comparison of fluoropyrimidine derivatives, capecitabine and 5'-deoxy-5-fluorouridine (5'-DFUR).
    Ebi H; Sigeoka Y; Saeki T; Kawada K; Igarashi T; Usubuchi N; Ueda R; Sasaki Y; Minami H
    Cancer Chemother Pharmacol; 2005 Aug; 56(2):205-11. PubMed ID: 15844007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacokinetic comparison of capecitabine and 5'-deoxy-5-fluorouridine (doxifluridine; 5'-DFUR)].
    Minami H; Ebi H
    Gan To Kagaku Ryoho; 2005 Dec; 32(13):2053-7. PubMed ID: 16352928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Higher capecitabine AUC in elderly patients with advanced colorectal cancer (SWOGS0030).
    Louie SG; Ely B; Lenz HJ; Albain KS; Gotay C; Coleman D; Raghavan D; Shields AF; Gold PJ; Blanke CD
    Br J Cancer; 2013 Oct; 109(7):1744-9. PubMed ID: 24022189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma disposition of capecitabine and its metabolites 5'DFCR and 5'DFUR in a standard and dose-intensified monotherapy regimen.
    Czejka M; Schueller J; Farkouh A; Gruenberger B; Scheithauer W
    Cancer Chemother Pharmacol; 2011 Mar; 67(3):613-9. PubMed ID: 20495919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A polymorphism in ABCA2 is associated with neutropenia induced by capecitabine in Japanese patients with colorectal cancer.
    Shibata Y; Matsumoto N; Murase R; Kubota Y; Ishida H; Shimada K; Fujita KI
    Cancer Chemother Pharmacol; 2023 Dec; 92(6):465-474. PubMed ID: 37653272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients.
    Gieschke R; Burger HU; Reigner B; Blesch KS; Steimer JL
    Br J Clin Pharmacol; 2003 Mar; 55(3):252-63. PubMed ID: 12630975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of pharmacokinetic variations of capecitabine after multiple administration in rats: a physiologically based pharmacokinetic model.
    Sakai S; Kobuchi S; Ito Y; Sakaeda T
    Cancer Chemother Pharmacol; 2020 May; 85(5):869-880. PubMed ID: 32240335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma disposition of capecitabine (CCB) and its metabolites 5'-deoxy-5-fluorocytidine (5'-DFCR) and 5'-deoxy-5-fluorouracil (5'-DFUR) with two different capecitabine/oxaliplatin dosage regimens.
    Farkouh A; Schueller J; Scheithauer W; Czejka M
    Int J Clin Pharmacol Ther; 2010 Jul; 48(7):487-8. PubMed ID: 20557855
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.